Liver Disease clinical trials at UC Davis
4 research studies open to eligible people
Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Sacramento, California and other locations
HM15211(Efocipegtrutide) in Subjects
open to eligible people ages 18-70
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Sacramento, California and other locations
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
“Comparison of imaging techniques used to evaluate patients with liver disease”
open to eligible people ages 18 years and up
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.
Sacramento, California
Metabolic Responses to Bariatric Surgery
“Using tissue samples to better understand the metabolism and genetics of obesity”
open to eligible people ages 18-55
Research the genetic and biomechanical markers of human adipose tissue on patients with morbid obesity. Additional tissue/fluid collection is also gathered during the time of surgery.
Sacramento, California
Our lead scientists for Liver Disease research studies include Mohamed R Ali, MD Guobao Wang.
Last updated: